Bacteria - Anchoring Hybrid Liposome Capable of Absorbing Multiple Toxins for Antivirulence Therapy of Escherichia coli Infection
Lixian Jiang,Yuying Zhu,Pengwei Luan,Jiazhen Xu,Ge Ru,Jian-Guo Fu,Nina Sang,Yang Xiong,Yuwei He,Guo-Qiang Lin,Jianxin Wang,Jiange Zhang,Ruixiang Li
DOI: https://doi.org/10.1021/acsnano.0c04800
IF: 17.1
2021-02-19
ACS Nano
Abstract:Antivirulence therapy by cell membrane coated nanoparticles has shown promise against bacterial infections. However, current approaches remain unsatisfactory when facing <i>Escherichia coli</i> (<i>E. coli</i>) infections, since the <i>E. coli</i> secretes multiple bacterial toxins including endotoxins and exotoxins that are challenging to eliminate simultaneously. What is worse, the absorptive scavengers normally rely on random contact of the diffuse toxins, which is not efficient. For the current cell membrane coated platform, the single type of cell membrane cannot fully meet the detoxing requirement facing multiple toxins. To address these problems, a polymyxin B (PMB)-modified, red blood cell (RBC)-mimetic hybrid liposome (P-RL) was developed. The P-RL was fabricated succinctly through fusion of PMB-modified lipids and the RBC membranes. By the strong interaction between PMB and the <i>E. coli</i> membrane, P-RL could attach and anchor to the <i>E. coli</i>; attributed to the fused RBC membrane and modified PMB, the P-RL could then efficiently neutralize both endotoxins and exotoxins from the toxin fountainhead. <i>In vitro</i> and <i>in vivo</i> results demonstrated the P-RL had a significant anchoring effect to <i>E. coli</i>. Moreover, compared with the existing RBC vesicles or PMB-modified liposomes, P-RL exhibited a superior therapeutic effect against RBC hemolysis, macrophage activation, and a mixed-toxin infection in mice. Potently, P-RL could inhibit <i>E. coli</i> O157:H7-induced skin damage, intestinal infection, and mouse death. Overall, the P-RL could potentially improve the detoxing efficiency and markedly expand the detoxification spectrum of current antivirulence systems, which provides different insights into drug-resistant <i>E. coli</i> treatment.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.0c04800?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.0c04800</a>.Figures S1–S19, methods and results of PMB lipid synthesis, expression of HlyA, neutralization of α-hemolysin and <i>E. coli</i> O157:H7 toxin, macrophage activation model, therapeutic effect of P-RL in mixed-toxin model, therapeutic effect of P-RL at different infection stages and degrees, therapeutic effect of P-RL on intestinal infection model, biocompatibility of P-RL (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.0c04800/suppl_file/nn0c04800_si_001.docx">DOCX</a>)This article has not yet been cited by other publications.
materials science, multidisciplinary,chemistry, physical,nanoscience & nanotechnology